Company

Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report

CompanyDrug

Japan’s MHLW Approves Eisai and BioArctic’s Leqembi for Alzheimer’s Treatment

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates

CompanyDrug

Novartis’ Lutathera Meets Primary Endpoint in Phase III Trial for GEP-NETs

CompanyDrug

AffaMed Therapeutics’ Luminate Receives Clinical Trial Approval for Dry AMD in China

CompanyDrug

Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors

Drug

Shanghai Junshi’s Tuoyi Meets Primary Efficacy Endpoint in Phase III Melanoma Study

CompanyDrug

Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC

Policy / Regulatory

CDE Introduces New Guidelines for Generic Drug Quality and Efficacy Consistency Evaluation

CompanyDrug

Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment

CompanyDrug

Abbisko Therapeutics’ Irpagratinib Receives FDA Clearance for Phase I Study in HCC

CompanyDrug

Sino Biopharmaceutical Submits IND Application for AT2R Antagonist TRD205 to FDA